A Phase 1 interventional study of Desogestrel/ethinyl estradiol and ethinyl estradiol and 28-day drospirenone oral contraceptive in Follicle Development, Ovarian Follicle and Follicle Count, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 2 sites in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-08.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Desogestrel/ethinyl estradiol and ethinyl estradiol
Drug: 28-day drospirenone oral contraceptive
Drug: 28-day levonorgestrel oral contraceptive
Drug pages: Desogestrel · Ethinyl Estradiol
Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
Drospirenone/ethinyl estradiol 0.3/0.02 mg
Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
Evaluation of ovarian follicular development by the Hoogland and Skouby grading scale from baseline to week 16.
Time frame: 16 weeks
Change in serum Estradiol level from baseline to week 16.
Time frame: 16 weeks
Change in serum Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels from baseline to week 16.
Time frame: 16 weeks
Change in serum Progesterone level from baseline to week 20.
Time frame: 20 weeks
Change from baseline to week 15 in Prothrombin fragment 1 + 2 levels.
Time frame: 15 weeks
Change from baseline to week 15 in D-dimer.
Time frame: 15 weeks
Change from baseline to end of week 15 in Plasmin-Antiplasmin complex
Time frame: 15 weeks
Change from baseline to week 15 in APTT and ETP based activated protein-C resistance (APC).
Time frame: 15 weeks
Change from baseline to week 15 in Fibrinogen.
Time frame: 15 weeks
Change from baseline to week 15 in Plasminogen, Factor II, Factor VII, Factor VIII, Protein C, and Free and Total Protein S.
Time frame: 15 weeks
Change from baseline to week 15 in Tissue Plasminogen Activator (t-PA).
Time frame: 15 weeks
Change from baseline to week 15 in Antithrombin.
Time frame: 15 weeks
Change from baseline to week 15 in Tissue Factor Pathway Inhibitor (TFPI).
Time frame: 15 weeks
Change from baseline to week 15 in Total Cortisol and Corticosteroid Binding Globulin (CBG).
Time frame: 15 weeks
Change from baseline to week 15 in Thyroid Stimulating Hormone (TSH).
Time frame: 15 weeks
Change from baseline to week 15 in Sex Hormone Binding Globulin (SHBG).
Time frame: 15 weeks
Return to ovulation rate at week 20.
Time frame: Week 20
Ran from Jan 2011 to primary completion in Mar 2012, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Desogestrel · Ethinyl Estradiol
Teva Branded Pharmaceutical Products R&D, Inc. →